Immuneering Corporation Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Immuneering Corporation (IMRX) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 13.81 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-05
- Immuneering Corporation antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 13.86M shares, a 66.20% increase year-over-year.
- Immuneering Corporation antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 8.34M shares, a 30.80% increase year-over-year.
- Immuneering Corporation antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 6.37M shares, a 20.45% increase year-over-year.
- Immuneering Corporation antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 5.29M shares, a 42.41% increase year-over-year.
- Immuneering Corporation antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 11.10M shares, a 73.91% increase from fiscal 2024.
- Immuneering Corporation antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 6.38M shares, a 16.12% increase from fiscal 2023.
- Immuneering Corporation antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 5.50M shares, a 54.43% increase from fiscal 2022.
- Immuneering Corporation antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 3.56M shares, a 24.46% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | 13.81M shares 10-Q · filed 2026-08-05 | |||||
| 2026-03-31 | 13.86M shares 10-Q · filed 2026-05-15 | |||||
| 2025-12-31 | 11.10M shares 10-K · filed 2026-03-06 | |||||
| 2025-09-30 | 11.17M shares 10-Q · filed 2025-11-12 | |||||
| 2025-06-30 | 8.41M shares 10-Q · filed 2026-08-05 | |||||
| 2025-03-31 | 8.34M shares 10-Q · filed 2026-05-15 | |||||
| 2024-12-31 | 6.38M shares 10-K · filed 2026-03-06 | |||||
| 2024-09-30 | 6.60M shares 10-Q · filed 2025-11-12 | |||||
| 2024-06-30 | 6.60M shares 10-Q · filed 2025-08-13 | |||||
| 2024-03-31 | 6.37M shares 10-Q · filed 2025-05-05 | |||||
| 2023-12-31 | 5.50M shares 10-K · filed 2025-03-20 | |||||
| 2023-09-30 | 5.49M shares 10-Q · filed 2024-11-13 | |||||
| 2023-06-30 | 5.45M shares 10-Q · filed 2024-08-06 | |||||
| 2023-03-31 | 5.29M shares 10-Q · filed 2024-05-07 | |||||
| 2022-12-31 | 3.56M shares 10-K · filed 2024-03-01 | |||||
| 2022-09-30 | 3.60M shares 10-Q · filed 2023-11-09 | |||||
| 2022-06-30 | 3.83M shares 10-Q · filed 2023-08-03 | |||||
| 2022-03-31 | 3.72M shares 10-Q · filed 2023-05-04 | |||||
| 2021-12-31 | 2.86M shares 10-K · filed 2023-03-06 | |||||
| 2021-09-30 | 2.76M shares 10-Q · filed 2022-11-10 | |||||
| 2021-06-30 | 2.67M shares 10-Q · filed 2022-08-10 | 14.61M shares 10-Q · filed 2021-09-09 | ||||
| 2021-03-31 | 2.86M shares 10-Q · filed 2022-05-10 | |||||
| 2020-12-31 | 10.67M shares 10-K · filed 2022-03-10 | 5.57M shares 10-Q · filed 2021-09-09 | ||||
| 2020-09-30 | 5.96M shares 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |